Lumicitabine
CR108375
Phase 2 small_molecule completed
Quick answer
Lumicitabine for Respiratory Syncytial Virus Infections is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed